Search Results - "LATHIA, C. D"

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development by Lathia, CD, Amakye, D, Dai, W, Girman, C, Madani, S, Mayne, J, MacCarthy, P, Pertel, P, Seman, L, Stoch, A, Tarantino, P, Webster, C, Williams, S, Wagner, JA

“…The acceptance and use of either surrogate end points (SEPs) or efficient clinical end points are associated with greater and more rapid availability of new…”
Get full text

Development of a chiral HPLC method to evaluate in vivo enantiomeric inversion of an unstable, polar radiosensitizer in plasma by Kagel, J.R, Rossi, D.T, Hoffman, K.L, Leja, B, Lathia, C.D

“…A chiral HPLC method to quantify in vivo enantiomeric inversion of prodrug CI-1010 ( I R ) or its drug II R (PD 146923), a radiosensitizer, upon X-irradiation…”
Get full text

Management of nonmatrix interfering peaks in a chiral high-performance liquid chromatographic assay produced by solid-phase extraction of rat plasma by Kagel, J.R., Rossi, D.T., Lathia, C.D.

“…PD 146923, under evaluation as an alkylating radiosensitizing drug, contains one chiral center and one chemically reactive aziridine ring. A method was…”
Get full text

Validated HPLC/MS/MS assay for CI-1011 in rat plasma and a comparison with an HPLC/UV assay by Bullen, William W., Lathia, Chetan D., Abel, Robert B., Hayes, Roger N.

“…A liquid chromatographic/mass spectrometric (LC/MS/MS) method to quantitate CI-1011 in rat plasma has been validated and compared to an LC/UV assay. The…”
Get full text

An HPLC assay utilizing solid-phase extraction for CI-1010, an alkylating radiosensitizer, in rat plasma by Bullen, William W., Rossi, David T., Hoffman, Keith L., Suri, Ajit, Lathia, Chetan D.

“…CI-1010, a 2-nitroimidazole, is a chiral prodrug for the active moiety PD 146923 and is under development as an alkylating radiosensitizer to be used as an…”
Get full text

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors by SKLARIN, N. T, LATHIA, C. D, BENSON, L, GROVE, W. R, THOMAS, S, ROCA, J, EINZIG, A. I, WIERNIK, P. H

“…CI-980 is a synthetic mitotic inhibitor that binds to the colchicine binding site of tubulin. It demonstrates broad activity against human and murine tumor…”
Get full text

Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial by Lettieri, J. T., Mazzu, A. L., Huang, L., Lathia, C. D.

“…Abstract only…”
Get full text

Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) by Blumenschein, G. R., Molina, J. R., Lathia, C. D., Ong, T. J., Roth, D., Rajagopalan, P., Fossella, F. V., Kies, M. S., Marks, R. S., Adjei, A. A., Sundaresan, P. R.

“…Abstract only…”
Get full text

A pharmacokinetic (PK) and safety study of sorafenib plus capecitabine in advanced solid tumors by McKay, C. E., Infante, J., Jones, S., Bendell, J., Greco, F. A., Markus, T. M., Spigel, D. R., Yardley, D. A., Woudenberg, J., Lathia, C. D., Burris, H. A.

“…Abstract only e14548 Background: The addition of a multi-targeted kinase inhibitor such as sorafenib (S) to standard chemotherapy holds promise for improving…”
Get full text

Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment by Halstenson, C E, Wong, M O, Johnson, C A, Zimmerman, S W, Onorato, J J, Keane, W F, Doepner, M, Sia, L, Tantillo, K, Bansal, S

“…Tazobactam is a new derivative of penicillinic acid sulfone, which functions as an irreversible inhibitor of many beta-lactamases. The disposition of…”
Get more information

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma by Flaherty, K. T., Redlinger, M., Schuchter, L. M., Lathia, C. D., Weber, B. L., O’Dwyer, P. J.

“…Abstract only…”
Get full text

Biomarkers and surrogate endpoints: how and when might they impact drug development? by Lathia, Chetan D

“…As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human…”
Get full text

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin by Molina, Julian R, Reid, Joel M, Erlichman, Charles, Sloan, Jeff A, Furth, Alfred, Safgren, Stephanie L, Lathia, Chetan D, Alberts, Steven R

“…Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade the extracellular matrix during the processes of invasion, metastasis and…”
Get full text